Amgen to discontinue discounts on anemia drug: report (Reuters)
Reuters - Amgen Inc is halting some pricing practices that critics say were contributing to overuse of its flagship anemia drug Aranesp at a time of mounting concerns about the product’s safety, the New York Times said.
More: continued here
Recent Entries
- Chevron to shed 2,000 jobs, sell some assets (AP)
- Obama: Greece, facing bad days, has US as ally (AP)
- European stocks fall as markets mark dark anniversary (AFP)
- Kan. mulling new soda tax, raising other levies (AP)
- Stock investors ask: What’s the next big thing? (AP)
- Gas price rises seen gentler on consumer wallets (AP)
- Job openings up sharply in January to 2.7M (AP)
- Feds to probe cause of runaway Prius in Calif. (AP)
- Celebration was for fans - Terry
- George Clooney Isn’t Betting on Himself for Oscar Win
